News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Most viewed in the last 7 days from JAMA Oncology
Photo taken from JAMA Oncology/LinkedIn
Apr 3, 2024, 06:05

Most viewed in the last 7 days from JAMA Oncology

JAMA Oncology shared a post on LinkedIn:

“Most viewed in the last 7 days from JAMA Oncology: Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemo immunotherapy?”

Additional information.
Source: JAMA Oncology/LinkedIn

cancer cell death chemo-immunotherapy JAMA Oncology NSCLC OncoDaily Oncology patients
Special Coverage
Insight
Nov 13, 2024, 07:12
Luigi Lorini was awarded the 2024 Martin "Mac" Cheever Excellence in Clinical Trial Design Travel Award for Immunoprevention
Blog
Nov 12, 2024, 23:10
Hesham ElGhazaly: Empowering Women’s Health Through Solidarity
Blog
Nov 12, 2024, 23:07
Helen’s Journey with Breast Cancer - The Max Foundation
Blog
Nov 12, 2024, 22:58
Webinar on Lung Cancer Highlights from ESMO 2024 - SPCC
Blog
Nov 12, 2024, 22:56
Sanjay Juneja: The Challenge of Innovation in Cancer Treatment
Blog
Nov 12, 2024, 22:52
Session on cervical cancer screening programs and managing cervical pre-cancer in women living with HIV at IPVC 2024 - IARC
Blog
Nov 12, 2024, 22:50
Penilla Gunther: First time speaking at the POLITICO Europe Healthcare Summit
Blog
Nov 12, 2024, 22:46
Addressing AMR for Better Cancer Care During London Global Cancer Week - UICC
Blog
Nov 12, 2024, 22:43
Applications Open for 2025 CancerX Accelerator - CancerX Moonshot
Blog
Nov 12, 2024, 22:40
Wafik S. El-Deiry: Welcoming Dr. Dinara Ryspayeva to Brown University for Therapeutic Advances in Oncology
Celebrities
Nov 12, 2024, 19:50
Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More
Blog
Nov 12, 2024, 19:38
Alfredo Colina on comparing real-time multimodal analysis of CAR-T cells to more traditional phenotypic and functional assays